☰

Nichole Coleman, Ph.D. - Publications

Affiliations: 
2014 Chemistry University of California, Davis, Davis, CA 
Area:
Organic Chemistry, Medicine and Surgery
Tree Info Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Oliván-Viguera A, Valero MS, Pinilla E, Amor S, García-Villalón ÁL, Coleman N, Laría C, Calvín-Tienza V, García-Otín ÁL, Fernández-Fernández JM, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Badorrey R, Simonsen U, et al. Vascular reactivity profile of novel KC a 3.1-selective positive-gating modulators in the coronary vascular bed. Basic & Clinical Pharmacology & Toxicology. PMID 26821335 DOI: 10.1111/Bcpt.12560  0.525
2015 Oliván-Viguera A, Valero MS, Coleman N, Brown BM, Laría C, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Molecular Pharmacology. 87: 338-48. PMID 25468883 DOI: 10.1124/Mol.114.095745  0.541
2015 Coleman N, Nguyen HM, Cao Z, Brown BM, Jenkins DP, Zolkowska D, Chen YJ, Tanaka BS, Goldin AL, Rogawski MA, Pessah IN, Wulff H. The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 234-49. PMID 25256961 DOI: 10.1007/S13311-014-0305-Y  0.611
2015 Brown BM, Coleman N, Yarov-Yarovoy V, Wulff H. Positive KCa Channel Gating Modulators with Selectivity for KCa3.1 Biophysical Journal. 108: 20a. DOI: 10.1016/J.Bpj.2014.11.134  0.604
2014 Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Molecular Pharmacology. 86: 342-57. PMID 24958817 DOI: 10.1124/Mol.114.093286  0.606
2013 Lam J, Coleman N, Garing AL, Wulff H. The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion On Therapeutic Targets. 17: 1203-20. PMID 23883298 DOI: 10.1517/14728222.2013.823161  0.583
2013 Strøbæk D, Brown DT, Jenkins DP, Chen YJ, Coleman N, Ando Y, Chiu P, Jørgensen S, Demnitz J, Wulff H, Christophersen P. NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. British Journal of Pharmacology. 168: 432-44. PMID 22891655 DOI: 10.1111/J.1476-5381.2012.02143.X  0.564
2012 Bodendiek SB, Rubinos C, Trelles MP, Coleman N, Jenkins DP, Wulff H, Srinivas M. Triarylmethanes, a new class of cx50 inhibitors. Frontiers in Pharmacology. 3: 106. PMID 22685432 DOI: 10.3389/Fphar.2012.00106  0.627
Show low-probability matches.